A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)
EPOCH 的随机 II 期试验(艾滋病)
基本信息
- 批准号:7716685
- 负责人:
- 金额:$ 3.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-20 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS Malignancy ConsortiumAIDS-Related LymphomaB-Cell LymphomasComputer Retrieval of Information on Scientific Projects DatabaseCyclophosphamideCyclophosphamide/Doxorubicin/Etoposide/Prednisone/VincristineDisease remissionEtoposide/PrednisoneFundingGrantIn complete remissionInstitutionKyocristineMaintenance TherapyMonoclonal AntibodiesNational Cancer InstituteNewly DiagnosedPatientsPhasePurposeRandomizedRateResearchResearch PersonnelResourcesSourceTreatment ProtocolsUnited States National Institutes of Healthchemotherapyimprovedpilot trialrituximab
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
In pilot trials conducted at the National Cancer Institute, infusional chemotherapy with EPOCH (etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin (doroxubicin) is associated with durable complete remission in over 75% of patients with newly diagnosed AIDS-related lymphomas. The purpose of this trial is to determine if the addition of the monoclonal antibody rituximab to the EPOCH regimen will improve the complete remission rate and its durability in the treatment of newly diagnosed patients with AIDS-related B-cell lymphomas. In this multi-center trial sponsored by the NCI-AIDS Malignancy consortium, 70 patients will be randomized to receive either rituximab either given concurrently with ePOCH or as maintenance therapy.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDRA M LEVINE其他文献
ALEXANDRA M LEVINE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDRA M LEVINE', 18)}}的其他基金
A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY
每日给予 VEGF 反义寡核苷酸 (VEGF-AS) 的 I 期研究
- 批准号:
7716712 - 财政年份:2008
- 资助金额:
$ 3.93万 - 项目类别:
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)
EPOCH 的随机 II 期试验(艾滋病)
- 批准号:
7603909 - 财政年份:2006
- 资助金额:
$ 3.93万 - 项目类别:
A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY
每日给予 VEGF 反义寡核苷酸 (VEGF-AS) 的 I 期研究
- 批准号:
7603936 - 财政年份:2006
- 资助金额:
$ 3.93万 - 项目类别:
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)
EPOCH 的随机 II 期试验(艾滋病)
- 批准号:
7368206 - 财政年份:2005
- 资助金额:
$ 3.93万 - 项目类别:
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)
EPOCH 的随机 II 期试验(艾滋病)
- 批准号:
7200017 - 财政年份:2004
- 资助金额:
$ 3.93万 - 项目类别:
AMC 005--CHOP & TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS
AMC 005--斩波
- 批准号:
6421159 - 财政年份:2000
- 资助金额:
$ 3.93万 - 项目类别:
AMC 005--CHOP & TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS
AMC 005--斩波
- 批准号:
6263762 - 财政年份:1998
- 资助金额:
$ 3.93万 - 项目类别:
AIDS-ONCOLOGY CLINICAL SCIENTIST DEVELOPMENT PROGRAM
艾滋病肿瘤学临床科学家发展计划
- 批准号:
6173645 - 财政年份:1998
- 资助金额:
$ 3.93万 - 项目类别:
相似海外基金
HIV-driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
8606444 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
HIV-driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
8776710 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
HIV-driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
8976130 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
HIV driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
8776617 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
HIV-driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
8467219 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
New Models and Treatments for AIDS-related Lymphoma
艾滋病相关淋巴瘤的新模型和治疗方法
- 批准号:
8624673 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
HIV-driven B cell activation: role in the genesis of AIDS-related lymphoma
HIV 驱动的 B 细胞激活:在 AIDS 相关淋巴瘤发生中的作用
- 批准号:
9385176 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
New Models and Treatments for AIDS-related Lymphoma
艾滋病相关淋巴瘤的新模型和治疗方法
- 批准号:
8541226 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别: